Citius Pharmac Dl Stock Beneish M Score
| 47N Stock | EUR 3.29 0.00 0.00% |
CITIUS |
At this time, CITIUS PHARMAC's M Score is inapplicable. The earnings manipulation may begin if CITIUS PHARMAC's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by CITIUS PHARMAC executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of CITIUS PHARMAC's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-4.84
Beneish M Score - Inapplicable
Did you try this?
Run Volatility Analysis Now
Volatility AnalysisGet historical volatility and risk analysis based on latest market data |
| All Next | Launch Module |
About CITIUS PHARMAC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CITIUS PHARMAC DL's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CITIUS PHARMAC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CITIUS PHARMAC DL based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in CITIUS Stock
CITIUS PHARMAC financial ratios help investors to determine whether CITIUS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CITIUS with respect to the benefits of owning CITIUS PHARMAC security.